Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Sanofi Consumer
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 210 | 225 | 222 | 172 | 160 | 171 | 173 | 221 | 234 | 251 | 229 |
| Expenses + | 116 | 135 | 140 | 109 | 97 | 109 | 109 | 151 | 149 | 161 | 140 |
| Operating Profit | 95 | 90 | 82 | 64 | 63 | 62 | 64 | 70 | 85 | 90 | 89 |
| OPM % | 45% | 40% | 37% | 37% | 39% | 36% | 37% | 32% | 36% | 36% | 39% |
| Other Income + | 1 | 1 | 3 | -24 | 3 | 2 | 5 | 12 | 3 | 5 | 6 |
| Interest | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 | 3 | 3 |
| Profit before tax | 95 | 90 | 84 | 39 | 61 | 63 | 67 | 79 | 84 | 90 | 91 |
| Tax % | 25% | 24% | 25% | 25% | 26% | 29% | 25% | 23% | 25% | 27% | 25% |
| Net Profit + | 71 | 68 | 63 | 29 | 45 | 44 | 50 | 61 | 63 | 66 | 68 |
| EPS in Rs | 12.59 | 19.54 | 19.24 | 21.71 | 26.36 | 27.31 | 28.87 | 29.44 |
Financials of Sanofi Consumer
Annual income statement trend
| Dec 2023 8m | Dec 2024 | Mar 2025 | Dec 2025 | TTM | |
|---|---|---|---|---|---|
| Sales + | 555 | 724 | 878 | 878 | 935 |
| Expenses + | 337 | 454 | 569 | 569 | 601 |
| Operating Profit | 219 | 271 | 309 | 309 | 334 |
| OPM % | 39% | 37% | 35% | 35% | 36% |
| Other Income + | 2 | -15 | 25 | 25 | 25 |
| Interest | 0 | 4 | 2 | 2 | 2 |
| Depreciation | 2 | 4 | 12 | 12 | 13 |
| Profit before tax | 219 | 247 | 320 | 320 | 344 |
| Tax % | 25% | 27% | 25% | 25% | |
| Net Profit + | 165 | 181 | 240 | 240 | 258 |
| EPS in Rs | 78.59 | 104.25 | 104.25 | 111.98 | |
| Dividend Payout % | 6% | 70% | 0% | 0% |
Financials of Sanofi Consumer
Capital structure and asset base
| Dec 2023 | Dec 2024 | Jun 2025 | |
|---|---|---|---|
| Equity Capital | 2 | 23 | 23 |
| Reserves | 206 | 250 | 234 |
| Borrowings + | 0 | 20 | 28 |
| Other Liabilities + | 138 | 138 | 137 |
| Total Liabilities | 345 | 431 | 422 |
| Fixed Assets + | 5 | 29 | 42 |
| CWIP | 3 | 1 | 0 |
| Investments | 0 | 0 | 0 |
| Other Assets + | 338 | 402 | 380 |
| Total Assets | 345 | 431 | 422 |
Financials of Sanofi Consumer
Operating, investing and financing cash movement
| Dec 2023 | Dec 2024 | Mar 2025 | Dec 2025 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -0 | 439 | ||
| Cash from Investing Activity + | 0 | 2 | ||
| Cash from Financing Activity + | 2 | -116 | ||
| Net Cash Flow | 2 | 325 | ||
| Free Cash Flow | -4 | 429 | ||
| CFO/OP | 2% | 208% |
Financials of Sanofi Consumer
Working capital efficiency and return ratios
| Dec 2023 | Dec 2024 | Mar 2025 | Dec 2025 | |
|---|---|---|---|---|
| Debtor Days | 21 | 7 | ||
| Inventory Days | 232 | 80 | ||
| Days Payable | 144 | 138 | ||
| Cash Conversion Cycle | 109 | -51 | ||
| Working Capital Days | 134 | -33 | ||
| ROCE % | 111% |
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…